THE MARTINIQUE PRINCIPLES IN RADIOIODINE THERAPY OF DIFFERENTIATED THYROID CANCER
T. M. Geliashvili,
V. V. Krylov,
P. I. Garbuzov,
A. A. Rodichev,
A. Yu. Shurinov,
T. Yu. Kochetova,
K. M. Petrosyan,
E. V. Borodavina https://doi.org/10.22328/2079-5343-2020-11-3-20-24
Abstract
The latest recommendations of the American Thyroid Association have caused serious disagreements between the nuclear medicine and endocrinologist communities regarding the radioactive iodine use. In 2018 eighteen experts from 8 countries and 4 leading organizations (ATA, EANM, SNMMI and ETA) met for the first time to establish mutual understanding in the role of radioiodine therapy for differentiated thyroid cancer. After much discussion and exchange of experience, the participants developed a consensus document based on the so-called nine principles of Martinique. We present an overview of the article published 2019 in Thyroid, entitled «Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association».
About the Authors
T. M. Geliashvili
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
V. V. Krylov
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
P. I. Garbuzov
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
A. A. Rodichev
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
A. Yu. Shurinov
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
T. Yu. Kochetova
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
K. M. Petrosyan
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
E. V. Borodavina
Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the Ministry
Russian Federation
Obninsk
Russian Federation
Obninsk
References
1. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer // Thyroid. 2016. Vol. 26. P. 1–133. DOI: 10.1089/thy.2015.0020.
2. Verburg F.A., Aktolun C., Chiti A. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer // Eur. J. Nucl. Med. Mol. Imaging. 2016. Vol. 43. P. 1001–1005. DOI: 10.1007/s00259-016-3327-3.
3. Tuttle R.M., Ahuja S., Avram A.M. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association // Thyroid. 2019. Vol. 29. P. 461–470. DOI: 10.1089/thy.2018.0597.
4. Van Nostrand D. Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer // Endocrinol Metab. Clin. North Am. 2017. Vol. 46. P. 783–793. DOI: 10.1016/j.ecl.2017.04.007.
5. Mu Z.Z., Zhang X., Lin Y.S. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer // Chonnam. Med. J. 2019. Vol. 55 (3). P. 127–135. DOI: 10.4068/cmj.2019.55.3.127.
6. Thies E.D., Tanase K., Maeder U., Luster M., Buck A.K., Hanscheid H., Reiners C., Verburg F.A. The number of 131-I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2014. Vol. 41. P. 2281–2290. DOI: 10.1007/s00259-014-2851-2.
Review
For citations:
Geliashvili T.M., Krylov V.V., Garbuzov P.I., Rodichev A.A., Shurinov A.Yu., Kochetova T.Yu., Petrosyan K.M., Borodavina E.V. THE MARTINIQUE PRINCIPLES IN RADIOIODINE THERAPY OF DIFFERENTIATED THYROID CANCER. Diagnostic radiology and radiotherapy. 2020;11(3):20-24. (In Russ.) https://doi.org/10.22328/2079-5343-2020-11-3-20-24
Views:
1024
Email this article 